Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer

Trial Profile

Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Niraparib (Primary)
  • Indications Ovarian cancer
  • Focus Expanded access; Therapeutic Use
  • Sponsors TESARO
  • Most Recent Events

    • 13 Apr 2017 Status changed from recruiting to completed.
    • 19 Jan 2017 New trial record
    • 17 Jan 2017 According to a Tesaro Inc. media release, an expanded access program for niraparib in Europe is planned to open in the first half of 2017, and will be initiated on a country-by-country basis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top